Search

Your search keyword '"McArthur, H."' showing total 530 results

Search Constraints

Start Over You searched for: Author "McArthur, H." Remove constraint Author: "McArthur, H."
530 results on '"McArthur, H."'

Search Results

2. P125 Neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy followed by adjuvant pembrolizumab vs placebo for early TNBC: surgical outcomes from the phase 3 KEYNOTE-522 study

5. The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group

6. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study

8. 1611P Health-related quality of life, vaccine uptake and immune response among cancer patients undergoing treatment during the COVID-19 pandemic

10. Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer

11. Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials

14. KEYNOTE-756: A randomized, double-blind, phase III study of pembrolizumab or placebo with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early-stage, ER+/HER2−breast cancer

16. Thawing, refreezing and frozen storage effects on muscle functionality and sensory attributes of frozen cod (Gadus morhua)

17. 1LBA LBA Oral - Adjuvant chemotherapy with or without atezolizumab for stage II and III triple-negative breast cancer: final analysis of the ALEXANDRA/ IMpassion030 phase 3 trial.

18. Abstract OT3-04-03: KEYNOTE-756: A randomized, double-blind, phase III study of pembrolizumab versus placebo in combination with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk early-stage ER+/HER2– breast cancer

19. Abstract OT3-05-02: ALEXANDRA/IMpassion030: A phase III study of standard adjuvant chemotherapy with or without atezolizumab in early triple negative breast cancer

24. Phase Ib/II open-label study of Ad-RTS-hIL-12 + veledimex gene therapy in chemotherapy-responsive locally advanced or metastatic breast cancer patients

25. A network approach to developing immuno-oncology combinations in Canada.

29. FEATURED ABSTRACT, Tumor and systemic immune responses to pre-operative cryoablation plus immune therapy with ipilimumab in early stage breast cancer

32. Effects of a green tea extract, Polyphenon E, on systemic biomarkers of growth factor signalling in women with hormone receptor-negative breast cancer

35. Abstract P4-13-01: A pilot study of pre-operative (Pre-op), single-dose ipilimumab (Ipi) and/or cryoablation (Cryo) in women (pts) with early stage/resectable breast cancer (ESBC)

38. Standardized uptake value (SUV) by positron emission tomography/computed tomography (PET/CT) as a prognostic variable in metastatic breast cancer (MBC).

39. 3:30 PM, Abstract No. 286 - FEATURED ABSTRACT, Tumor and systemic immune responses to pre-operative cryoablation plus immune therapy with ipilimumab in early stage breast cancer

43. Troponins Do Not Predict Cardiotoxicity in a Pilot Study of Adjuvant Bevacizumab (B) Plus Dose-Dense Doxorubicin/Cyclophosphamide (AC) Followed by Nanoparticle Albumin-Bound Paclitaxel (nab-P).

45. Adjuvant dose-dense doxorubicin-cyclophosphamide x 4 with or without bevacizumab is safe: no evidence of short-term changes in left ventricular ejection fraction.

46. Incidence and severity of sensory neuropathy (SN) with bevacizumab (B) added to dose-dense (dd) doxorubicin/cyclophosphamide (AC) followed by nanoparticle albumin-bound (nab) paclitaxel (P) in patients (pts) with early stage breast cancer (BC)

47. Dose-dense (dd) doxorubicin-cyclophosphamide (AC) X 4 and short-term changes in left ventricular ejection fraction (LVEF) alone or with bevacizumab (B) in patients (pts) with early stage breast cancer (BC)

Catalog

Books, media, physical & digital resources